Sun, Dec 28, 2014, 7:46 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

BioCryst Pharmaceuticals, Inc. Message Board

  • hardluckchuck2002 hardluckchuck2002 Sep 15, 2012 10:53 AM Flag

    BioCryst Pharmaceuticals Inc Files Patent Application for Pyrrolo [1, 2-B] Pyridazine Derivatives as Janus Kinase Inhibitors

    New Delhi, Sept. 15 -- USA based BioCryst Pharmaceuticals Inc filed patent application for pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors. The inventors are Babu Yarlagadda S, Kotian Pravin L, Kumar V Satish, Wu Minwan and Lin Tsu-Hsing.

    BioCryst Pharmaceuticals Inc filed the patent application on Feb. 6, 2012. The patent application number is 291/MUMNP/2012 A. The international classification number is C07D 487/04.

    According to the Controller General of Patents, Designs & Trade Marks, "The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Does anybody know what this is about? The last sentence "... and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I" is intriguing.

      From wikipedia: "Janus kinase inhibitor is a class of medicines that function by inhibiting the effect of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), interfering with the JAK-STAT signaling pathway.
      Some JAK2 inhibitors are under development for the treatment of polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.[1] Some inhibitors of JAK2 are in clinical trials, e.g. for psoriasis.[2]
      JAK3 is also being targeted for a variety of inflammatory diseases, and one has had good results in a phase II trial for rheumatoid arthritis.[3]

      PS: Thanks for posting Hardluck.

    • Hey JACKO, NO ONE CARES. Does this help the company SELL ANYTHING, make money or stop their CASH BURN to BK? Well, there ya go.

      Sentiment: Strong Sell

12.005+0.175(+1.48%)Dec 26 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQFri, Dec 26, 2014 4:00 PM EST
RLI Corp.
NYSEFri, Dec 26, 2014 4:08 PM EST